The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Cortexyme built a drug called atuzaginstat to block gingipains. Phase 1 was clean. They ran a 643-patient Phase 2/3 trial called GAIN. The FDA hit it with a partial clinical hold for liver toxicity. The drug missed both primary endpoints. In August 2022 Cortexyme shut the program down, renamed itself Quince, and pivoted to bone disease.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.